A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Indolent B-cell Lymphoma Clinical Trial

Official title:

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06343935
• Other study ID #: YY-20394-014
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 30, 2024
• Est. completion date: April 30, 2025

Study information

• Verified date: April 2024
• Source: Shanghai YingLi Pharmaceutical Co. Ltd.
• Contact: Jun Ma
• Phone: 0451-84883471
• Email: majun0322[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode).

Description:

This is a national multicenter, randomized controlled, open, dose-optimized Phase IV study. It is expected to enroll approximately 88 patients with relapsed/refractory indolent B-cell lymphoma. The aim is to evaluate the efficacy and safety of linperlisib in the treatment of patients with relapsed/refractory indolent B-cell lymphoma at two doses/modes of administration (clinically recommended dose/mode and optimized dose/mode).

Patients were divided to two groups by stratified randomization according to tumor type (FL, CLL/SLL, MZL, others) during the screening period. Both groups were orally administered with a starting dose of 80mg qd for 21 days. On the 21st day of the 4th cycle, if the patient's tumor does not progress and there is no intolerable toxicity, after the researchers determined that medication could be continued, one group of patients continued to take 80mg qd dose continuously, and the other group of patients continued to take 80mg qd dose continuously for two weeks per cycle and stopped for one week, and safety and tumor efficacy evaluation were conducted regularly. The maximum duration of treatment is two years until the disease progresses, toxicity becomes intolerable, or the investigator determines that it is not appropriate to continue treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 88
• Est. completion date: April 30, 2025
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with r/r indolent B-cell lymphoma confirmed by histology or cytology, mainly follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma (MZL), and lymphoplasmacytic lymphoma/macroglobulinemia (LPL/WM),

2. ECOG performance status (PS) 0 ~ 2 points,

3. Expected survival =3 months,

5) At least one measurable lesion was present in patients other than CLL, LPL/WM; 6) Good organ function level, 7) The elution period from the end of previous anti-tumor therapy (including radiotherapy, chemotherapy, immunotherapy, surgery or molecular targeted therapy) to participation in this trial is =4 weeks, in which the elution period of small-molecule targeted drugs and Chinese medicines with anti-tumor effects is =14 days.

Exclusion Criteria:

1. Those who have progressed with antitumor drugs targeting PI3Kd (except for those who cannot tolerate them),

2. There is a third space effusion (such as a large amount of pleural fluid and ascites) that the investigators judge to be uncontrollable,

3. Steroid hormone dosage (equivalent amount of prednisone) was greater than 20mg/ day for 4 weeks before enrollment, and continuous use was more than 14 days,

4. Inability to swallow, chronic diarrhea or intestinal obstruction, there are multiple factors that affect drug use and absorption,

5. Allergic constitution, or known allergic history of the drug components,

6. Patients with active viral, bacterial or fungal infections (such as pneumonia) within 4 weeks prior to enrollment; Or had uncontrolled pulmonary fibrosis, acute lung disease, or interstitial lung disease within 4 weeks prior to enrollment,

7. Infected with HBV and HCV,

8. History of immune deficiency,

9. Moderate or severe heart disease,

10. Have undergone major surgery within 28 days before signing informed consent, or plan to undergo major surgery during the study period,

11. The first study of patients with a history of other malignancies within 5 years prior to drug administration (except for patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or other cancers in situ without disease recurrence within 2 years),

12. Received autologous hematopoietic stem cell transplantation within 90 days before the first medication,

Related Conditions & MeSH terms

• Indolent B-cell Lymphoma
• Lymphoma

Intervention

Drug:
• Linperlisib
Linperlisib is a small molecule inhibitor of phosphoinositol 3-kinase-d (PI3K-d)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai YingLi Pharmaceutical Co. Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	The time from the first dose of study treatment to first documented disease progression or death due to any cause, whichever occurs first.	From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months
Secondary	Objective response rate	The proportion of subjects who have a Complete Response or Partial Response	From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months
Secondary	Overall survival	The time from the first dose of study treatment to death for any reason.	From the first dose to the date of death from any cause, whichever comes first,up to 24months
Secondary	Adverse event	Incidence of adverse events evaluated by NCI CTCAE v5.0 and associated dose of linperlisib	From enrollment receiving Linperlisib to 30 days after the last linperlisib treatment.
Secondary	Serious adverse event	Incidence of serious adverse event and associated dose of linperlisib	From enrollment receiving Linperlisib to 30 days after the last linperlisib treatment.